CECelanese Corporation
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.
Priced for a decline (~−7% a year). Little growth is priced in even as revenue fell 2% a year over three years, potential value, or a value trap.
Expensive vs its own history: P/E 13.8 vs a 10.0 median over 34 quarters (+38% vs median).
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CE's price assumes
Today's price asks for −7.5% free cash flow growth a year; over the last three years Celanese Corporation delivered −13%, the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 13%
Free cash flow yield · Chemicals median 13%
- Growth the price implies
- −7.5%
Growth the price implies · The price pays for −7.5% free cash flow growth a year for a decade; the business has delivered −13% a year over the last three.
- Price / book
- 1.29
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.29
- EV / EBIToperating margin −7.1%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.65
- Free cash flow, trailing twelve months
- $708M
- Market capitalisation
- $5.36B
- 3-year revenue growth
- −1.9%
- 3-year free cash flow growth
- −13%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.